Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $14.45 billion. The enterprise value is $14.77 billion.
Important Dates
The next estimated earnings date is Wednesday, February 11, 2026, after market close.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 61.38 million shares outstanding. The number of shares has increased by 5.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.38M |
| Shares Change (YoY) | +5.57% |
| Shares Change (QoQ) | -4.94% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 80.87% |
| Float | 60.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 102.00 |
| PS Ratio | 18.70 |
| Forward PS | 12.12 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.70 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.99 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.69% |
| Return on Invested Capital (ROIC) | -12.99% |
| Return on Capital Employed (ROCE) | -82.18% |
| Weighted Average Cost of Capital (WACC) | 7.15% |
| Revenue Per Employee | $745,912 |
| Profits Per Employee | -$268,740 |
| Employee Count | 1,017 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.30 |
Taxes
In the past 12 months, Ascendis Pharma has paid $11.28 million in taxes.
| Income Tax | 11.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +87.09% in the last 52 weeks. The beta is 0.45, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +87.09% |
| 50-Day Moving Average | 209.99 |
| 200-Day Moving Average | 188.68 |
| Relative Strength Index (RSI) | 66.60 |
| Average Volume (20 Days) | 629,534 |
Short Selling Information
| Short Interest | 3.45M |
| Short Previous Month | 3.39M |
| Short % of Shares Out | 6.78% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.77 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $758.59 million and -$273.31 million in losses. Loss per share was -$4.54.
| Revenue | 758.59M |
| Gross Profit | 658.46M |
| Operating Income | -162.24M |
| Pretax Income | -262.03M |
| Net Income | -273.31M |
| EBITDA | -156.88M |
| EBIT | -162.24M |
| Loss Per Share | -$4.54 |
Full Income StatementBalance Sheet
The company has $632.51 million in cash and $954.65 million in debt, with a net cash position of -$322.14 million or -$5.25 per share.
| Cash & Cash Equivalents | 632.51M |
| Total Debt | 954.65M |
| Net Cash | -322.14M |
| Net Cash Per Share | -$5.25 |
| Equity (Book Value) | -204.24M |
| Book Value Per Share | -3.34 |
| Working Capital | 36.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$125.16 million and capital expenditures -$6.43 million, giving a free cash flow of -$132.64 million.
| Operating Cash Flow | -125.16M |
| Capital Expenditures | -6.43M |
| Free Cash Flow | -132.64M |
| FCF Per Share | -$2.16 |
Full Cash Flow StatementMargins
Gross margin is 86.80%, with operating and profit margins of -21.39% and -36.03%.
| Gross Margin | 86.80% |
| Operating Margin | -21.39% |
| Pretax Margin | -34.54% |
| Profit Margin | -36.03% |
| EBITDA Margin | -20.68% |
| EBIT Margin | -21.39% |
| FCF Margin | n/a |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.56% |
| Shareholder Yield | -5.56% |
| Earnings Yield | -1.89% |
| FCF Yield | -0.92% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $264.13, which is 12.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $264.13 |
| Price Target Difference | 12.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 45.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 0.74 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 4 |
